

ASX/Media Release

Additional Information for AGM

29th November 2006, Melbourne: The Board of Directors of Benitec Limited (ASX:BLT) hereby advise that the following information is provided pursuant to Resolution 7 - Re-Approval of Employee Share Option Plan for the Company's Annual General Meeting, which is being held tomorrow at 2.00pm at the Mezzanine Room , Morgans @ 401, 401 Collins Street, Melbourne.

Options Issued under Plan

The Employee Share Option Plan was previously approved by shareholders on 25 February 2002. The following options have been issued under the plan since that date:

Expiry Date	Exercise Price	No. of Options Issued
28-Jul-09	\$0.50	190,000
28-Jul-09	\$1.00	175,000
28-Jul-09	\$1.50	187,500
28-Jul-09	\$2.00	187,500
30-Sep-13	\$0.03	271,249
30-Sep-13	\$0.07	2,927
16-Jun-12	\$0.145	5,830,000
19-Jun-12	\$0.145	3,540,000
TOTAL		10,384,176

This information has been previously disclosed in the Company's Annual Report.

Voting Exclusion Statement

For the purposes of this Resolution, the Company will disregard any votes cast by any person who participated in an issue and any person who might obtain a benefit, except a benefit solely in the capacity of the security holder, if this Resolution is passed and any person associated with those persons. However, the Company need not disregard a vote if it is cast by a person as proxy for a person who is entitled to vote, in accordance with the directions on the proxy form or it is cast by the person chairing the meeting as proxy for a person who is entitled to vote, in accordance with a direction on the proxy form to vote as the proxy decides.

INQUIRIES:

Sue MacLeman
Chief Executive Officer
+61 437 211 200

Rudi Michelson
Monsoon Communications
+61 411 402 737

About Benitec

Benitec is an Australian biotechnology company focused on developing therapeutics to treat serious diseases using its proprietary ddRNAi technology. The company's main therapeutic program is in the area of Human Immunodeficiency Virus (HIV). Benitec's RNA-based HIV therapeutic, co-developed with the Center for Biomedicine & Genetics at the City of Hope in Los Angeles, California, will enter Phase I clinical trials in 2006. For additional information, please visit www.benitec.com.

